Neuropace Inc — Balance Sheet (NASDAQ:NPCE) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Total assets 133.56 M114.11 M107.65 M94.65 M Total liabilities 60.06 M79.33 M87 M86.63 M Total equity 73.5 M34.78 M20.65 M8.01 M Total liabilities & shareholders' equities 133.56 M114.11 M107.65 M94.65 M Total debt ———— Net debt ————

Notizie

LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates

Obiettivo di prezzo per le azioni NeuroPace alzato a $20 da $19 da Leerink Partners

NeuroPace stock price target raised to $20 from $19 at Leerink Partners

NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright

NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Il titolo di NeuroPace sale mentre UBS ribadisce il rating Buy dopo forti ricavi nel Q4

NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue

NeuroPace registra una crescita dei ricavi del 25% per il 2025, prevede crescita costante

NeuroPace reports 25% revenue growth for 2025, projects steady growth